News >

PARP Inhibitor Approvals Offer Ovarian Cancer Patients New Hope

Gina Columbus @ginacolumbusonc
Published: Sunday, Apr 16, 2017

Lyndsay J. Willmott, MD

Lyndsay J. Willmott, MD

The ovarian cancer treatment paradigm underwent another transformation near the end of 2016 with the FDA approval of the PARP inhibitor rucaparib (Rubraca) for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication